APA
Proetel U., Pletsch N., Lauseker M., Müller M. C., Hanfstein B., Krause S. W., Kalmanti L., Schreiber A., Heim D., Baerlocher G. M., Hofmann W., Lange E., Einsele H., Wernli M., Kremers S., Schlag R., Müller L., Hänel M., Link H., Hertenstein B., Pfirrman M., Hochhaus A., Hasford J., Hehlmann R. & Saußele S. (20140804). Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. : Annals of hematology.
Chicago
Proetel Ulrike, Pletsch Nadine, Lauseker Michael, Müller Martin C, Hanfstein Benjamin, Krause Stefan W, Kalmanti Lida, Schreiber Annette, Heim Dominik, Baerlocher Gabriela M, Hofmann Wolf-Karsten, Lange Elisabeth, Einsele Hermann, Wernli Martin, Kremers Stephan, Schlag Rudolf, Müller Lothar, Hänel Mathias, Link Hartmut, Hertenstein Bernd, Pfirrman Markus, Hochhaus Andreas, Hasford Joerg, Hehlmann Rüdiger and Saußele Susanne. 20140804. Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. : Annals of hematology.
Harvard
Proetel U., Pletsch N., Lauseker M., Müller M. C., Hanfstein B., Krause S. W., Kalmanti L., Schreiber A., Heim D., Baerlocher G. M., Hofmann W., Lange E., Einsele H., Wernli M., Kremers S., Schlag R., Müller L., Hänel M., Link H., Hertenstein B., Pfirrman M., Hochhaus A., Hasford J., Hehlmann R. and Saußele S. (20140804). Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. : Annals of hematology.
MLA
Proetel Ulrike, Pletsch Nadine, Lauseker Michael, Müller Martin C, Hanfstein Benjamin, Krause Stefan W, Kalmanti Lida, Schreiber Annette, Heim Dominik, Baerlocher Gabriela M, Hofmann Wolf-Karsten, Lange Elisabeth, Einsele Hermann, Wernli Martin, Kremers Stephan, Schlag Rudolf, Müller Lothar, Hänel Mathias, Link Hartmut, Hertenstein Bernd, Pfirrman Markus, Hochhaus Andreas, Hasford Joerg, Hehlmann Rüdiger and Saußele Susanne. Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. : Annals of hematology. 20140804.